Neuromyelitis Optica Spectrum Disorder Clinical Trials

64 clinical trials for Neuromyelitis Optica Spectrum Disorder across international registries, including 23 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) — RECRUITING · PHASE3
• A Phase III, Multicenter, Open-Label, Uncontrolled Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) — RECRUITING · PHASE3
• Biomarkers in Autoimmune Disease of Nervous System — RECRUITING
• Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder — RECRUITING · NA
• Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies — RECRUITING
• Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. — RECRUITING · PHASE1
• Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases — RECRUITING · PHASE1
• Study of Ultomiris® (Ravulizumab) Safety in Pregnancy — RECRUITING
• CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD) — RECRUITING
• Ofatumumab in AQP4-IgG Seropositive NMOSD — RECRUITING · PHASE1
• Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy — RECRUITING
• French Registry for Monitoring Pregnancies for Multiple Sclerosis — RECRUITING
• Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder — RECRUITING · PHASE2
• Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD — RECRUITING · NA
• Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) — RECRUITING
• Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System — RECRUITING · PHASE1
• Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD) — RECRUITING · NA
• A PHASE 2/3, OPEN-LABEL, HISTORICAL-CONTROLLED, SINGLE-ARM, MULTICENTER SMDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF RAVULIZUMAB IN CHILDREN AND ADOLESCENTS WITH AQUAPORIN-4 ANTIBODY POSITIVE (AQP4-AB [+]) NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) — RECRUITING · PHASE2
• SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION — RECRUITING
• A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) — RECRUITING
• A PHASE 2/3 OPEN-LABEL, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND ACTIVITY OF ECULIZUMAB IN PEDIATRIC PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA SPECTRUM DISORDER — RECRUITING · PHASE2
• A PHASE 3, EXTERNAL PLACEBO-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RAVULIZUMAB IN ADULT PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY, OF SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA (NMO) AND NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) — RECRUITING · PHASE3
• A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD) — TERMINATED · PHASE3
• Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia — TERMINATED
• Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool — NOT_YET_RECRUITING
• A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy — NOT_YET_RECRUITING · PHASE1
• Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD — ACTIVE_NOT_RECRUITING · PHASE2
• Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) — NOT_YET_RECRUITING · PHASE3
• An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder — TERMINATED · PHASE2
• The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders — ACTIVE_NOT_RECRUITING
• Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) — ACTIVE_NOT_RECRUITING · PHASE4
• An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD — COMPLETED · PHASE3
• A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) — ACTIVE_NOT_RECRUITING · PHASE3
• Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder — COMPLETED
• Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder — NOT_YET_RECRUITING · PHASE1
• Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders — ACTIVE_NOT_RECRUITING · PHASE2
• A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention — TERMINATED · PHASE4
• A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) — COMPLETED · PHASE3
• A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder — TERMINATED · PHASE2
• Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders — OTHER
• A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients — NOT_YET_RECRUITING · PHASE1
• Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) — COMPLETED · PHASE2
• FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack — OTHER · PHASE2
• Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder — COMPLETED · PHASE2
• A PHASE I, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF SATRALIZUMAB IN ADULT PATIENTS WITH APQ4 ANTIBODY-POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER WITH BODYWEIGHT >100 KG — COMPLETED · PHASE1
• Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases — OTHER
• An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients — COMPLETED · PHASE3
• AN OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INEBILIZUMAB IN PEDIATRIC SUBJECTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER — NOT_YET_RECRUITING
• A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder — OTHER · NA

Refine this search